Table 1 Comparison between anti-integrin αvβ6 antibody-positive and anti-integrin αvβ6 antibody-negative patients with ICI-induced colitis.
Anti-integrin αvβ6 antibodies | |||
|---|---|---|---|
Positive | Negative | P value | |
Number of patients, n | 8 | 18 | |
Median age, years (range) | 69 (57–82) | 70.5 (47–80) | 0.404 |
Sex | |||
Male, n (%) | 5 (62.5) | 13 (72.2) | 0.667 |
Female, n (%) | 3 (37.5) | 5 (27.8) | |
Endoscopic findings | |||
Number of typical UC findings (median) | 4.5 | 1.5 | <0.001 |
Cancer type, n (%) | |||
Non-small cell lung cancer | 2 (25) | 6 (33.3) | 0.815 |
Melanoma | 3 (37.5) | 4 (22.2) | |
Kidney cancer | 1 (12.5) | 4 (22.2) | |
Esophageal cancer | 1 (12.5) | 1 (5.6) | |
Peritoneal cancer | 1 (12.5) | 0 (0) | |
Cancer of unknown primary | 0 (0) | 1 (5.6) | |
Malignant pleural mesothelioma | 0 (0) | 1 (5.6) | |
Bladder cancer | 0 (0) | 1 (5.6) | |
ICI medication, n (%) | |||
Pembrolizumab | 4 (50) | 6 (33.3) | 0.429 |
Nivolumab | 3 (37.5) | 5 (27.8) | |
Nivolumab and ipilimumab | 0 (0) | 5 (27.8) | |
Atezolizumab | 1 (12.5) | 1 (5.6) | |
Durvalumab | 0 (0) | 1 (5.6) | |
Grade ≥ 3 adverse events, n (%) | |||
Diarrhea | 5 (62.5) | 7 (38.9) | 0.401 |
Colitis | 6 (75) | 1 (5.6) | 0.001 |
Treatment, n (%) | |||
Steroid alone | 3 (37.5) | 12 (66.7) | 0.218 |
Conservative treatment | 1 (12.5) | 6 (33.3) | 0.375 |
Steroid/infliximab | 4 (50) | 0 (0) | 0.005 |
Prognosis, n (%) | |||
Alive | 4 (50) | 12 (66.7) | 0.664 |
Dead | 4 (50) | 6 (33.3) | |
